North America Biosimilars Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028

Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)

No. of Pages: 166
Report Code: BMIRE00028371
Category: Life Sciences
North America Biosimilars Market

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. North America Biosimilars Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. North America Biosimilars Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. North America Biosimilars Market Regional Analysis

6.2 North America Biosimilars Market Revenue 2020-2028 (US$ Million)
6.3 North America Biosimilars Market Forecast Analysis

7. North America Biosimilars Market Analysis – by Disease Indication

7.1 Cancer
  • 7.1.1 Overview
  • 7.1.2 Cancer: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.2 Diabetes
  • 7.2.1 Overview
  • 7.2.2 Diabetes: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.3 Autoimmune Diseases
  • 7.3.1 Overview
  • 7.3.2 Autoimmune Diseases: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.4 Other Diseases
  • 7.4.1 Overview
  • 7.4.2 Other Diseases: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

8. North America Biosimilars Market Analysis – by Drug Class

8.1 Granulocyte Colony-Stimulating Factors
  • 8.1.1 Overview
  • 8.1.2 Granulocyte Colony-Stimulating Factors: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.2 Human Growth Hormone
  • 8.2.1 Overview
  • 8.2.2 Human Growth Hormone: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.3 Insulin
  • 8.3.1 Overview
  • 8.3.2 Insulin: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.4 TNF Blockers & Monoclonal Antibodies
  • 8.4.1 Overview
  • 8.4.2 TNF Blockers & Monoclonal Antibodies: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.5 Erythropoietin-Stimulating Agents
  • 8.5.1 Overview
  • 8.5.2 Erythropoietin-Stimulating Agents: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

9. North America Biosimilars Market Analysis – by Route of Administration

9.1 Intravenous
  • 9.1.1 Overview
  • 9.1.2 Intravenous: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.2 Subcutaneous
  • 9.2.1 Overview
  • 9.2.2 Subcutaneous: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

10. North America Biosimilars Market Analysis – by End User

10.1 Hospitals
  • 10.1.1 Overview
  • 10.1.2 Hospitals: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.2 Speciality Clinics
  • 10.2.1 Overview
  • 10.2.2 Speciality Clinics: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.3 Homecare
  • 10.3.1 Overview
  • 10.3.2 Homecare: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

11. North America Biosimilars Market – North America Analysis

11.1 Overview

11.2 North America
  • 11.2.1 North America Biosimilars Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 11.2.1.1 North America Biosimilars Market – Revenue and Forecast Analysis – by Country
  • 11.2.1.1 US: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.1.1 US: North America Biosimilars Market Breakdown, by Disease Indication
    • 11.2.1.1.2 US: North America Biosimilars Market Breakdown, by Drug Class
    • 11.2.1.1.3 US: North America Biosimilars Market Breakdown, by Route of Administration
    • 11.2.1.1.4 US: North America Biosimilars Market Breakdown, by End User
  • 11.2.1.2 Canada: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.2.1 Canada: North America Biosimilars Market Breakdown, by Disease Indication
    • 11.2.1.2.2 Canada: North America Biosimilars Market Breakdown, by Drug Class
    • 11.2.1.2.3 Canada: North America Biosimilars Market Breakdown, by Route of Administration
    • 11.2.1.2.4 Canada: North America Biosimilars Market Breakdown, by End User
  • 11.2.1.3 Mexico : North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.3.1 Mexico : North America Biosimilars Market Breakdown, by Disease Indication
    • 11.2.1.3.2 Mexico : North America Biosimilars Market Breakdown, by Drug Class
    • 11.2.1.3.3 Mexico : North America Biosimilars Market Breakdown, by Route of Administration
    • 11.2.1.3.4 Mexico : North America Biosimilars Market Breakdown, by End User

12. Competitive Landscape

12.1 Heat Map Analysis
12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments

14. Company Profiles

14.1 Amgen Inc
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
14.2 Celltrion Inc
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
14.3 Sanofi SA
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
  • 14.3.6 Key Developments
14.4 Biocon Ltd
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
14.5 Coherus BioSciences Inc
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
14.6 Eli Lilly and Co
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments
14.7 Sandoz AG
  • 14.7.1 Key Facts
  • 14.7.2 Business Description
  • 14.7.3 Products and Services
  • 14.7.4 Financial Overview
  • 14.7.5 SWOT Analysis
  • 14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
  • 14.8.1 Key Facts
  • 14.8.2 Business Description
  • 14.8.3 Products and Services
  • 14.8.4 Financial Overview
  • 14.8.5 SWOT Analysis
  • 14.8.6 Key Developments
14.9 Pfizer Inc
  • 14.9.1 Key Facts
  • 14.9.2 Business Description
  • 14.9.3 Products and Services
  • 14.9.4 Financial Overview
  • 14.9.5 SWOT Analysis
  • 14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
  • 14.10.1 Key Facts
  • 14.10.2 Business Description
  • 14.10.3 Products and Services
  • 14.10.4 Financial Overview
  • 14.10.5 SWOT Analysis
  • 14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights
15.2 List of Abbreviations

The List of Companies - North America Biosimilars Market

  • Amgen Inc
  • Celltrion Inc
  • Sanofi SA
  • Biocon Ltd
  • Coherus BioSciences Inc
  • Eli Lilly and Co
  • Sandoz AG
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Dr. Reddy's Laboratories Ltd
  • Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)